Dennis L. Citrin

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Heather Han, Véronique Dièras, Mark E. Robson et al. · Annals of Oncology · 2017 · 206 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

Stephen Johnston, Maureen Trudeau, Bella Kaufman et al. · Journal of Clinical Oncology · 2008 · 194 citations · Full text

Medicine, Oncology, Pharmacology +17

The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.

Ignac Fogelman, R. G. Bessent, John G. Turner et al. · PubMed · 1978 · 192 citations

Medicine, Nuclear Medicine, Radiology +17

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

Denise A. Yardley, Robert Weaver, Michelle Melisko et al. · Journal of Clinical Oncology · 2015 · 189 citations · Full text

Medicine, Oncology, Pharmacology +17